Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 40: 2247-2253, 1994;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Winkler, M.
Right arrow Articles by Pichlmayr, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Winkler, M.
Right arrow Articles by Pichlmayr, R.

Clinical Chemistry, Vol 40, 2247-2253, Copyright © 1994 by American Association for Clinical Chemistry

Plasma vs whole blood for therapeutic drug monitoring of patients receiving FK 506 for immunosuppression

M Winkler, B Ringe, J Baumann, M Loss, K Wonigeit and R Pichlmayr
Klinik fur Abdominal- und Transplantationschirurgie, Medizinische Hochschule, Hannover, Germany.

By retrospective analysis of 13,000 blood samples obtained from 248 patients receiving FK 506 therapy, we compared the suitability of plasma with that of whole blood as the matrix for therapeutic drug monitoring of FK 506. The plasma concentrations did not correlate with the concentrations in whole blood (r = 0.56). In contrast to plasma samples (analyzed by enzyme immunoassay), FK 506 was detectable in all whole-blood samples (analyzed by enzyme immunoassay/microparticle enzyme immunoassay). The inter- and intraindividual variations of FK 506 measurements were greater in plasma than in whole blood. Moreover, plasma concentrations correlated only poorly with clinical events. There was a tendency to greater plasma concentrations being measured during episodes of toxicity, but no clear difference was evident between stable course and rejection. In whole-blood specimens, a correlation between reduced or increased FK 506 concentrations and rejection or toxicity, respectively, was observed. The discriminatory power of whole-blood values was greater for the differentiation between toxicity and stable course than between rejection and stable course. We therefore recommend whole blood rather than plasma as the matrix for therapeutic monitoring of FK 506 concentrations.


The following articles in journals at HighWire Press have cited this article:


Home page
 Journal of the American Animal Hospital AssociationHome page
J. D. Griffies, C. L. Mendelsohn, W. S. Rosenkrantz, R. Muse, M. J. Boord, and C. E. Griffin
Topical 0.1% Tacrolimus for the Treatment of Discoid Lupus Erythematosus and Pemphigus Erythematosus in Dogs
J. Am. Anim. Hosp. Assoc., January 1, 2004; 40(1): 29 - 41.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
C. Staatz, P. Taylor, and S. Tett
Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation
Nephrol. Dial. Transplant., September 1, 2001; 16(9): 1905 - 1909.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
B. V. Karanam, R. R. Miller, A. Colletti, T. Montgomery, K. D. Carey, T. Hawkins, Y. S. Tang, M. Lavin, R. A. Stearns, S. H. L. Chiu, et al.
Disposition of L-732,531, a Potent Immunosuppressant, in Rats and Baboons
Drug Metab. Dispos., October 1, 1998; 26(10): 949 - 957.
[Full Text]

Home page
 Clin. Chem.Home page
U. C. Garg, G. Austin, C. Barnes, and M. Hamilton
Comparison of the Abbott IMx Tacrolimus I and Tacrolimus II Assays
Clin. Chem., August 1, 1998; 44(8): 1783 - 1785.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1994 by the American Association for Clinical Chemistry.